This is a StreetInsider.com Premium Only Page

Pieris Pharma (PIRS) – StreetInsider.com Reports

Apr 19, 2024 12:13 PM Pieris Pharma (PIRS) Announces 1-for-80 Reverse Stock Split

Apr 18, 2024 04:24 PM Pieris Pharma (PIRS) Approves 1:80 Share Buyback

Mar 27, 2024 08:03 AM Pieris Pharma (PIRS) Announces Strategy to Maximize Partnered Milestone and Royalty Potential

Aug 17, 2023 08:03 AM Pieris Pharma (PIRS) Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342

Jul 18, 2023 09:16 AM Pieris Pharma (PIRS) Provides Strategic Update and Announces Restructuring

Jul 18, 2023 09:10 AM Pieris Pharma (PIRS) Halted, News Pending

Jun 21, 2023 07:09 AM Pieris Pharma (PIRS) to Resume Trading at 7:30 a.m.

Jun 21, 2023 07:03 AM Pieris Pharma (PIRS) Announces AstraZeneca's (AZN) Discontinuation of Phase 2a Trial of Elarekibep

Jun 21, 2023 06:55 AM Pieris Pharma (PIRS) Halted, News Pending

May 4, 2023 08:02 AM Pieris Pharma (PIRS) Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep

Mar 29, 2023 04:57 PM U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.00%

Mar 29, 2023 07:04 AM Pieris Pharma (PIRS) Reports FY22 Results, Provides Business Update

Jan 10, 2023 08:02 AM Pieris Pharma (PIRS) Receives $5M Milestone from Seagen for Initiation of Phase 1 Trial of CD228

Jun 23, 2022 11:05 AM Pieris Pharma (PIRS) received a decision to grant European patent number - Patent Grants

Jan 3, 2022 07:05 AM Pieris Pharma (PIRS) Reports Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402

Oct 6, 2021 08:03 AM Pieris Pharma (PIRS) Appoints Thomas Bures as CFO and Ahmed Mousa as Chief Business Officer

Aug 5, 2021 04:56 PM Pieris Pharma (PIRS) Files $250M Mixed Shelf

Jun 25, 2021 07:40 AM Pieris Pharma (PIRS) Shares Up 16% Following IPF Drug Candidate Announcement; $17M Grant

Jun 25, 2021 07:03 AM Pieris Pharma (PIRS) Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post-COVID-19

Jun 24, 2021 09:26 AM Pre-Open Stock Movers 06/24: (MRIN) (RCUS) (LLY) Higher; (PRTG) (RAD) (BIIB) Lower (more...)

Jun 24, 2021 08:01 AM Pieris Pharma (PIRS) Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer

May 26, 2021 09:23 AM Pre-Open Stock Movers 05/26: (NBRV) (PIRS) (GME) Higher; (LRMR) (LOTZ) (TVTX) Lower (more...)

May 25, 2021 05:57 PM After-Hours Stock Movers 05/25: (PIRS) (INSE) (ZS) Higher; (TVTX) (JWN) (PACK) Lower (more...)

May 25, 2021 05:54 PM Pieris Pharma (PIRS) Adds to Intra-Day Gains; Shares up 46% After-Hours

May 25, 2021 09:28 AM Pre-Open Stock Movers 05/25: (PIRS) (JYNT) (SHAK) Higher; (NOVN) (ADMP) (TLMD) Lower (more...)

May 25, 2021 09:05 AM Pieris Pharmaceuticals (PIRS) Jumps After Signing Another Milestone-Heavy Deal, Could Generate $1.4 Billion From a New Deal With Genentech

May 25, 2021 08:19 AM Pieris Pharma (PIRS) Surges 20% on Genentech Deal

May 25, 2021 08:08 AM Pieris Pharma (PIRS) Announces Respiratory and Ophthalmology Collaboration with Genentech

May 18, 2021 04:49 AM Jefferies Assumes Pieris Pharmaceuticals (PIRS) at Buy

Apr 26, 2021 08:14 AM Pieris Pharma (PIRS), Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific

Apr 12, 2021 06:13 AM Pieris Pharma (PIRS) Announces Updated Phase 1 Monotherapy Data for 4-1BB/HER2 Bispecific Cinrebafusp Alfa and Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/S095012

Jan 19, 2021 08:05 AM Pieris Pharma (PIRS) Reports FDA to Lift Partial Clinical Hold on PRS-343 Phase 1 Studies

Aug 10, 2020 06:35 AM Pieris Pharma (PIRS), Lilly (LLY) Enter Pact to Evaluate Combination of PRS-343 With Ramucirumab and Paclitaxel in Gastric Cancer

Jul 21, 2020 09:30 AM Pre-Open Movers 07/21: (NBEV) (LXRX) (OMI) Higher; (ACAD) (PIRS) (CTSO) Lower (more...)

Jul 20, 2020 05:52 PM After-Hours Stock Movers 07/20: (NBEV) (HIBB) (IBM) Higher; (ACAD) (PIRS) (KNSA) Lower (more...)

Jul 20, 2020 04:09 PM Pieris Pharma (PIRS) Announces FDA Partial Clinical Hold On PRS-343

Mar 13, 2020 04:30 AM Baird Upgrades Pieris Pharmaceuticals (PIRS) to Outperform

Jan 27, 2020 11:46 AM Pieris Pharmaceuticals (PIRS) PT Raised to $9 at H.C. Wainwright; PRS-080 News 'Not Surprising'

Jan 6, 2020 04:17 PM Pier 1 Imports (PIR) Reports Q3 Results, to Reduce Store Footprint by up to 450 Locations

Nov 11, 2019 05:41 AM Pieris Pharma (PIRS) Highlights Data Demonstrating Monotherapy Clinical Benefit with 4-1BB/HER2 Bispecific PRS-343 in Phase 1 Escalation Study

Sep 26, 2019 10:04 AM Pieris Pharma (PIRS), AstraZeneca (AZN) Highlights Multiple Ascending Dose Phase 1b Data for Inhaled IL4-Rα Antagonist AZD1402/PRS-060

Jul 30, 2019 09:29 AM UPDATE: Baird Downgrades Pieris Pharmaceuticals (PIRS) to Neutral

May 22, 2019 02:34 PM Pieris Pharma (PIRS), AstraZeneca (AZN) Present Single- Ascending Dose Phase 1a Data for Inhaled IL-4Rα Antagonist AZD1402/PRS-060 at ATS

May 14, 2019 08:16 AM UPDATE: Baird Starts Pieris Pharmaceuticals (PIRS) at Outperform

Apr 2, 2019 08:12 AM Pieris Pharma (PIRS) Presents Preclinical Data for GPC3/4-1BB Bispecific PRS-342 at AACR

Nov 8, 2018 06:18 AM Pieris Pharmaceuticals (PIRS) PT Lowered to $6.50 at Oppenheimer

Nov 7, 2018 12:01 PM Pieris Pharmaceuticals (PIRS) PT Lowered to $5 at H.C. Wainwright

Oct 25, 2018 08:45 AM Pieris Pharma (PIRS) Names Matthew L. Sherman M.D. to Board

Sep 10, 2018 08:06 AM Pieris Pharma (PIRS) Announces Peter Kiener, D.Phil. to Board

Sep 4, 2018 08:03 AM Pieris Pharma (PIRS) Reports Dosing of First Patient in Phase I Combination Trial for PRS-343 Plus Anti-PD-L1 Immunotherapy